newsfilter
← Latest News
Business Wire·

Acceleron Reports Third Quarter 2021 Financial Results

- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) - - Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd